Accéder au contenu
Merck

IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.

Blood (2013-07-23)
Hendrik Nogai, Sören-Sebastian Wenzel, Stephan Hailfinger, Michael Grau, Eva Kaergel, Volkhard Seitz, Brigitte Wollert-Wulf, Matthias Pfeifer, Annette Wolf, Mareike Frick, Kerstin Dietze, Hannelore Madle, Alexander Tzankov, Michael Hummel, Bernd Dörken, Claus Scheidereit, Martin Janz, Peter Lenz, Margot Thome, Georg Lenz
RÉSUMÉ

Constitutive activation of the nuclear factor-κ B (NF-κB) pathway is a hallmark of the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL). Recurrent mutations of NF-κB regulators that cause constitutive activity of this oncogenic pathway have been identified. However, it remains unclear how specific target genes are regulated. We identified the atypical nuclear IκB protein IκB-ζ to be upregulated in ABC compared with germinal center B-cell-like (GCB) DLBCL primary patient samples. Knockdown of IκB-ζ by RNA interference was toxic to ABC but not to GCB DLBCL cell lines. Gene expression profiling after IκB-ζ knockdown demonstrated a significant downregulation of a large number of known NF-κB target genes, indicating an essential role of IκB-ζ in regulating a specific set of NF-κB target genes. To further investigate how IκB-ζ mediates NF-κB activity, we performed immunoprecipitations and detected a physical interaction of IκB-ζ with both p50 and p52 NF-κB subunits, indicating that IκB-ζ interacts with components of both the canonical and the noncanonical NF-κB pathway in ABC DLBCL. Collectively, our data demonstrate that IκB-ζ is essential for nuclear NF-κB activity in ABC DLBCL, and thus might represent a promising molecular target for future therapies.